Plasminogen subcutaneous - Omnio/ProMetic Life Sciences

Drug Profile

Plasminogen subcutaneous - Omnio/ProMetic Life Sciences

Alternative Names: Subcutaneous Plasminogen (Human) 10

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Omnio AB
  • Developer ProMetic Life Sciences
  • Class Anti-inflammatories; Antithrombotics; Beta-globulins; Blood products and substitutes; Proteins
  • Mechanism of Action Fibrinolytic agents; Plasminogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diabetic foot ulcer; Ear disorders
  • Research Inflammation

Most Recent Events

  • 20 Feb 2018 Phase-I/II clinical trials in Diabetic foot ulcer in Sweden (SC) (EudraCT2016-004782-11)
  • 08 Nov 2017 Phase-I/II clinical trials in Ear disorders in Sweden (SC) (EudraCT2017-002927-68)
  • 01 Nov 2017 The Swedish Medical Products Agency approves Clinical Trial Application to initiate a clinical trial of plasminogen therapy in Ear disorders (chronic tympanic membrane perforation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top